Sirtex 1H14 earnings were in line with Morgans forecasts, with modest dose sales held up by FX, and ongoing brand-building activities limiting full translation...

Sirtex 1H14 earnings were in line with Morgans forecasts, with modest dose sales held up by FX, and ongoing brand-building activities limiting full translation into operating profit and bottom-line gains. Morgans believe near-term dose sales should be solid, the outlook over the medium/longer term remains less certain as it is contingent on favourable clinical results and commercial success, where we continue to express caution. Morgans make only modest changes to FY14-16 NPAT estimates, with our blended SOTP/risk-adjusted DCF-based target price increasing to A$12.17. (SRX, Hold, Price Target A$12.17)


The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.